text: <unk>  is a combination of two cystic fibrosis transmembrane conductance regulators that is FDA approved for the treatment of of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.   Common adverse reactions include dyspnea, nasopharyngitis, nausea, diarrhea, upper respiratory tract infection, fatigue, and rash.
option_0: Lumacaftor and ivacaftor
option_1: Tezacaftor / ivacaftor
option_2: Tiotropium bromide and olodaterol
option_3: Fluticasone/salmeterol
option_4: Hyquincarb
option_5: Beclomethasone dipropionate 
option_6: Fluticasone furoate
option_7: Glycopyrrolate and formoterol fumarate